EA2222 (Colorectal Cancer with Liver Metasases) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.
Colorectal Cancer That Has Metastasized to the Liver
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with unresectable colorectal cancer
- Have metastases to the liver
- Have received a 3-6 month course of previous first-line chemotherapy
- Have not received radiation therapy directed toward the liver
For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:
- Group 1 will get will get chemotherapy that’s given in the traditional manner and directly into the hepatic artery
- Group 2 will get will get chemotherapy that’s given in the traditional manner only
Study Details
